Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mark E. Willcox"'
Autor:
Jeanne E. Poole, Marye J. Gleva, Ulrika Birgersdotter‐Green, Kelley R. H. Branch, Rahul N. Doshi, Tariq Salam, Thomas C. Crawford, Mark E. Willcox, Arun M. Sridhar, Ghiath Mikdadi, Sean C. Beinart, Yong‐Mei Cha, Andrea M Russo, Ron K. Rowbotham, Joseph Sullivan, Laura M. Gustavson, Kaisa Kivilaid
Publikováno v:
Journal of Cardiovascular Electrophysiology. 33:831-842
A wearable cardioverter defibrillator (WCD) is indicated in appropriate patients to reduce the risk for sudden cardiac death. Challenges for patients wearing a WCD have been frequent false shock alarms primarily due to electrocardiogram noise and wea
Publikováno v:
Heart Rhythm O2
Background Clinicians rarely scrutinize the full disclosure of a myriad of FDA-approved long-term rhythm monitors, and they rely on manufacturers to detect and report relevant rhythm abnormalities. Objective The objective of this study is to compare
Publikováno v:
SSRN Electronic Journal.
Introduction: A myriad of long-term (>48 hr) cardiac rhythm monitors are available for use. Clinicians rarely scrutinize the full disclosure and thus rely on manufacturers to detect and report relevant rhythm abnormalities using processes that are op
Autor:
Jennifer A. Beckman, Santosh Rane, Nazem Akoum, Nahush A. Mokadam, Claudius Mahr, Mark E. Willcox
Publikováno v:
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 19(3)
A 67-year-old man implanted with a HeartWare LVAD for ischaemic cardiomyopathy as a bridge to cardiac transplantation presented with refractory monomorphic ventricular tachycardia despite optimized volume status, impeller speed, and heart failure, an
Publikováno v:
Trends in cardiovascular medicine. 26(6)
The subcutaneous implantable cardioverter-defibrillator (ICD) was developed as a simple device to reduce the morbidity of ICD therapy while providing a comparable reduction in sudden death from ventricular fibrillation. This review highlights the dif
Publikováno v:
Heart (British Cardiac Society). 102(2)
A 37-year-old man presents after a syncopal event. He has schizophrenia and bipolar disorder, for which, risperidone was recently started. On arrival, heart rate and blood pressure were normal, potassium was 3.2 meq/dL (0.82 mmol/L), magnesium was 2.
Autor:
Mark E. Willcox, Alan M. Speir, Shrinivas Hebsur, Sharon L. Hunt, Anthony J. Rongione, Linda Henry, Sari D. Holmes, Niv Ad
Publikováno v:
Journal of the American College of Cardiology. 57(14)
Autor:
Poole, Jeanne E.1 jpoole@u.washington.edu, Gleva, Marye J.2, Birgersdotter‐Green, Ulrika3, Branch, Kelley R. H.1, Doshi, Rahul N.4, Salam, Tariq5, Crawford, Thomas C.6, Willcox, Mark E.7, Sridhar, Arun M.1, Mikdadi, Ghiath8, Beinart, Sean C.9, Cha, Yong‐Mei10, Russo, Andrea M11, Rowbotham, Ron K.12, Sullivan, Joseph12, Gustavson, Laura M.12, Kivilaid, Kaisa13
Publikováno v:
Journal of Cardiovascular Electrophysiology. May2022, Vol. 33 Issue 5, p831-842. 12p. 3 Diagrams, 3 Charts, 2 Graphs.
Publikováno v:
Heart; Jan2016, Vol. 102 Issue 2, p163-164, 2p, 2 Graphs